Lenangio 5mg Capsule contains Lenalidomide, a potent immunomodulatory agent indicated primarily for the treatment of multiple myeloma and certain types of myelodysplastic syndromes. Lenalidomide exerts its therapeutic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells, thereby reducing tumor proliferation. It is often prescribed in combination with other chemotherapeutic agents or corticosteroids to enhance efficacy. The 5mg dosage is tailored for patients requiring lower dose regimens or dose adjustments based on renal function or tolerability. Lenangio should be administered under strict medical supervision due to its potential adverse effects, including hematologic toxicities such as neutropenia and thrombocytopenia, as well as risks of thromboembolism. Regular monitoring of blood counts and renal function is essential during therapy. Lenalidomide is contraindicated in pregnancy due to its teratogenic potential and requires adherence to risk management programs to prevent fetal exposure. Patients should be advised regarding possible side effects, including fatigue, rash, and gastrointestinal disturbances. Lenangio 5mg Capsule offers a targeted therapeutic option in hematologic malignancies, contributing to improved patient outcomes when integrated into comprehensive oncologic treatment protocols.